Application Note

Probing The Source Of An Unstable Impurity And Controlling Its Formation At Release

By Geraldine Su, Ken Strassberger, Craig Kramer, Xinqun Huang, Mike Markham, Adare Pharma Solutions

iStock-1169476198-team-solve-computer-desk

APT-76 is an anti-neoplastic agent and currently being developed as an extended-release formulation (enteric coating) for an ongoing early Phase 1 clinical trial. The finished drug product is a capsule filled with mini tablets. Two major issues related to impurities were encountered during the formulation and analytical stages.

Objectives

A critical step in an extended-release drug product analysis is the extraction during impurity and assay sample preparation. When both the drug substance and the impurity are unstable, this is especially challenging. This study is divided into three parts:

  1. Identification of the unstable impurity by LC/MS, and its mechanism of the formation.
  2. Probing the source of impurity formation during the extraction and manufacturing process.
  3. Improving the processing and extraction method to eliminate the formation of the impurity.
VIEW THE APPLICATION NOTE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Outsourced Pharma? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: